$6.88
4.25% yesterday
Nasdaq, Apr 03, 09:49 pm CET
ISIN
US04335A1051
Symbol
ARVN
Sector
Industry

Arvinas, Inc. Stock price

$6.90
-9.33 57.49% 1M
-17.58 71.81% 6M
-12.27 64.01% YTD
-31.69 82.12% 1Y
-66.44 90.59% 3Y
-32.83 82.63% 5Y
-9.15 57.01% 10Y
Nasdaq, Closing price Thu, Apr 03 2025
-0.28 3.90%
ISIN
US04335A1051
Symbol
ARVN
Sector
Industry

Key metrics

Market capitalization $474.53m
Enterprise Value $-554.97m
P/E (TTM) P/E ratio negative
EV/Sales (TTM) EV/Sales -3.45
P/S ratio (TTM) P/S ratio 2.95
P/B ratio (TTM) P/B ratio 0.85
Revenue growth (TTM) Revenue growth 105.10%
Revenue (TTM) Revenue $161.00m
Cash position $1.04b
P/E forward negative
P/S forward 2.48
EV/Sales forward negative
Short interest 13.18%
Show more

Is Arvinas, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Arvinas, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

22 Analysts have issued a Arvinas, Inc. forecast:

17x Buy
77%
5x Hold
23%

Analyst Opinions

22 Analysts have issued a Arvinas, Inc. forecast:

Buy
77%
Hold
23%

Financial data from Arvinas, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
161 161
105% 105%
100%
- Direct Costs 5 5
25% 25%
3%
161 161
124% 124%
100%
- Selling and Administrative Expenses - -
-
-
- Research and Development Expense - -
-
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT - -
-
-
Net Profit -150 -150
59% 59%
-93%

In millions USD.

Don't miss a Thing! We will send you all news about Arvinas, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Arvinas, Inc. Stock News

Neutral
GlobeNewsWire
about 2 hours ago
– Data demonstrate that ARV-102 was well tolerated, orally bioavailable, and brain-penetrant; ARV-102 achieved central and peripheral LRRK2 reduction indicating substantial LRRK2 protein degradation in healthy volunteers –
Neutral
GlobeNewsWire
8 days ago
– Company to highlight first-in-human data from healthy volunteers in both the single-ascending and multiple-ascending dose portions of a Phase 1 study of ARV-102, an investigational PROTAC LRRK2 degrader – – Company to highlight first-in-human data from healthy volunteers in both the single-ascending and multiple-ascending dose portions of a Phase 1 study of ARV-102, an investigational PROTAC ...
Negative
Investors Business Daily
24 days ago
Arvinas stock lost half its value Tuesday after the biotech company reported mixed results from its Pfizer-partnered breast cancer drug. The post Arvinas Plummets 53% On Mixed Results For Its Pfizer-Tied Breast Cancer Drug appeared first on Investor's Business Daily.
More Arvinas, Inc. News

Company Profile

Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110 and ARV-471. The company was founded in February 2013 and is headquartered in New Haven, CT.

Head office United States
CEO John Houston
Employees 430
Founded 2013
Website www.arvinas.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today